Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) EBT (2016 - 2026)

Pharma-Bio Serv's EBT history spans 17 years, with the latest figure at $36490.0 for Q1 2026.

  • For Q1 2026, EBT rose 278.1% year-over-year to $36490.0; the TTM value through Jan 2026 reached -$67421.0, up 86.18%, while the annual FY2025 figure was -$94260.0, 87.52% up from the prior year.
  • EBT reached $36490.0 in Q1 2026 per PBSV's latest filing, up from $4254.0 in the prior quarter.
  • In the past five years, EBT ranged from a high of $587451.0 in Q3 2023 to a low of -$290190.0 in Q3 2024.
  • Average EBT over 5 years is $121331.3, with a median of $36490.0 recorded in 2026.
  • Peak YoY movement for EBT: crashed 149.4% in 2024, then skyrocketed 278.1% in 2026.
  • A 5-year view of EBT shows it stood at $231044.0 in 2022, then crashed by 120.7% to -$47835.0 in 2023, then skyrocketed by 68.96% to -$14849.0 in 2024, then soared by 128.65% to $4254.0 in 2025, then skyrocketed by 757.78% to $36490.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's EBT are $36490.0 (Q1 2026), $4254.0 (Q4 2025), and -$209029.0 (Q3 2025).